| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors
|
Li, Xiao-yang
|
|
|
21 |
6 |
p. 534-544
|
artikel
|
| 2 |
Challenges in Management of Patients With Lung Cancer in Times of COVID-19: An Imaging Perspective
|
Gorospe, Luis
|
|
|
21 |
6 |
p. 568-570
|
artikel
|
| 3 |
Chr2 30297612-ALK, A Novel Intergenic Fusion With Exon18 of ALK, Responds to Crizotinib
|
Chen, Xiaofeng
|
|
|
21 |
6 |
p. e564-e566
|
artikel
|
| 4 |
Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Non–small-cell Lung Cancer
|
Tsimberidou, Apostolia M.
|
|
|
21 |
6 |
p. 477-481
|
artikel
|
| 5 |
Clinical Features in Patients With Malignant Pleural Mesothelioma With 5-Year Survival and Evaluation of Original Diagnoses
|
Paajanen, Juuso
|
|
|
21 |
6 |
p. e633-e639
|
artikel
|
| 6 |
Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report
|
Aubanel, Marjorie
|
|
|
21 |
6 |
p. e601-e606
|
artikel
|
| 7 |
Comparing Segmentectomy and Lobectomy for Clinical Stage IA Solid-dominant Lung Cancer Measuring 2.1 to 3 cm
|
Kamigaichi, Atsushi
|
|
|
21 |
6 |
p. e528-e538
|
artikel
|
| 8 |
Consolidative Radiotherapy in Oligometastatic Lung Cancer: Patient Selection With a Prediction Nomogram
|
Friedes, Cole
|
|
|
21 |
6 |
p. e622-e632
|
artikel
|
| 9 |
Diabetes, Metformin, and Lung Cancer: Retrospective Study of the Korean NHIS-HEALS Database
|
Kim, Joungyoun
|
|
|
21 |
6 |
p. e551-e559
|
artikel
|
| 10 |
Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab
|
Guerini, Andrea Emanuele
|
|
|
21 |
6 |
p. e547-e550
|
artikel
|
| 11 |
Duration of Targeted Therapy in Patients With Advanced Non–small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis
|
Reckamp, Karen L.
|
|
|
21 |
6 |
p. 545-552.e1
|
artikel
|
| 12 |
Editorial Board
|
|
|
|
21 |
6 |
p. A1
|
artikel
|
| 13 |
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study
|
Luciani, Andrea
|
|
|
21 |
6 |
p. e567-e571
|
artikel
|
| 14 |
Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC
|
Yan, Yan
|
|
|
21 |
6 |
p. 562-567
|
artikel
|
| 15 |
EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature
|
Batra, Ullas
|
|
|
21 |
6 |
p. e597-e600
|
artikel
|
| 16 |
First-iGAP: A Randomized Placebo-Controlled Phase II Study of First-line Intercalated Gefitinib and Pemetrexed-Cisplatin Chemotherapy for Never-Smoker Lung Adenocarcinoma Patients
|
Lee, Youngjoo
|
|
|
21 |
6 |
p. e572-e582
|
artikel
|
| 17 |
First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non–Small-Cell Lung Cancer
|
Zheng, Jing
|
|
|
21 |
6 |
p. 509-519.e1
|
artikel
|
| 18 |
Frequent Mutations of POT1 Distinguish Pulmonary Sarcomatoid Carcinoma From Other Lung Cancer Histologies
|
Shen, Erica
|
|
|
21 |
6 |
p. e523-e527
|
artikel
|
| 19 |
Gender-based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma
|
Barsky, Andrew R.
|
|
|
21 |
6 |
p. e583-e591
|
artikel
|
| 20 |
Imaging in Therapy Response Assessment and Surveillance of Lung Cancer: Evidenced-based Review With Focus on the Utility of 18F-FDG PET/CT
|
Sheikhbahaei, Sara
|
|
|
21 |
6 |
p. 485-497
|
artikel
|
| 21 |
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
|
Cortellini, Alessio
|
|
|
21 |
6 |
p. 498-508.e2
|
artikel
|
| 22 |
Impact of a Hybrid Lung Cancer Screening Model on Patient Outcomes and Provider Behavior
|
Hirsch, Erin A.
|
|
|
21 |
6 |
p. e640-e646
|
artikel
|
| 23 |
Leucine-Rich α2-Glycoprotein as a Potential Biomarker for Immune-related Colitis After Anti–PD-L1 Therapy: A Report of a Case Series
|
Yoshimura, Katsuhiro
|
|
|
21 |
6 |
p. e516-e522
|
artikel
|
| 24 |
Maintaining Equipoise With Maintenance Therapy in Mesothelioma
|
Mansfield, Aaron S.
|
|
|
21 |
6 |
p. 482-484
|
artikel
|
| 25 |
Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non–small-cell Lung Cancer
|
Gijtenbeek, Rolof G.P.
|
|
|
21 |
6 |
p. e647-e653
|
artikel
|
| 26 |
Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis
|
Frost, Nikolaj
|
|
|
21 |
6 |
p. e607-e621
|
artikel
|
| 27 |
Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer
|
Hall, Peter E.
|
|
|
21 |
6 |
p. 527-533
|
artikel
|
| 28 |
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non–Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)
|
Patel, Jyoti D.
|
|
|
21 |
6 |
p. 520-526
|
artikel
|
| 29 |
Primary CNS Metastatic BRAF-mutated Lung Adenocarcinoma With Complete Intracranial Response to BRAF/MEK Inhibition
|
Tsakonas, Georgios
|
|
|
21 |
6 |
p. e544-e546
|
artikel
|
| 30 |
Primary Extra-axial Chordoma Masquerading as Lung Cancer: Case Report and Review of the Literature
|
Ball, Somedeb
|
|
|
21 |
6 |
p. e560-e563
|
artikel
|
| 31 |
Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901
|
Dudek, Arkadiusz Z.
|
|
|
21 |
6 |
p. 553-561.e1
|
artikel
|
| 32 |
Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non–Small-Cell Lung Cancer
|
Gelatti, Ana C.Z.
|
|
|
21 |
6 |
p. e511-e515
|
artikel
|
| 33 |
Table of Contents
|
|
|
|
21 |
6 |
p. A3-A8
|
artikel
|
| 34 |
The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors
|
Friedlaender, Alex
|
|
|
21 |
6 |
p. e539-e543
|
artikel
|
| 35 |
Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non–small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834)
|
Miura, Satoru
|
|
|
21 |
6 |
p. e592-e596
|
artikel
|
Tijdschrift beschrijving